Last reviewed 2026-06-02 · How we verify

Nanvuranlat

J-Pharma Co., Ltd. · Phase 3 active Small molecule ✓ Verified Jun 2026

Nanvuranlat is a Small molecule drug developed by J-Pharma Co., Ltd.. It is currently in Phase 3 development.

Nanvuranlat is being studied in a clinical trial for the treatment of Advanced Biliary Tract Cancer and Biliary Tract Cancer (BTC). The trial, NCT07265674, is comparing the efficacy of Nanvuranlat to Physician's Best Choice in participants aged 18 years or older with Biliary Tract Cancer.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Nanvuranlat
Sponsor	J-Pharma Co., Ltd.
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nanvuranlat CI brief — competitive landscape report
Nanvuranlat updates RSS · CI watch RSS
J-Pharma Co., Ltd. portfolio CI

Frequently asked questions about Nanvuranlat

What is Nanvuranlat?

Nanvuranlat is a Small molecule drug developed by J-Pharma Co., Ltd..

Who makes Nanvuranlat?

Nanvuranlat is developed by J-Pharma Co., Ltd. (see full J-Pharma Co., Ltd. pipeline at /company/j-pharma-co-ltd).

What development phase is Nanvuranlat in?

Nanvuranlat is in Phase 3.

Manufacturer: J-Pharma Co., Ltd. — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing